The deal, offering $2 billion up front and $2 billion in future milestone payments, includes a gene therapy manufacturing facility and a pipeline that includes treatments for Parkinson's and congestive heart failure.
The company acquired 10 AAV-based gene therapies in development for lysosomal storage disorders, including two already in early clinical trials.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
AstraZeneca subsidiary and California-based firm to develop AAV-based therapy for chronic lung disease.